You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

~ Buy the ARISTADA (aripiprazole lauroxil) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ARISTADA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ARISTADA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01469039 ↗ A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia Completed Alkermes, Inc. Phase 3 2011-12-01 The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
NCT02634320 ↗ A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Completed Alkermes, Inc. Phase 4 2015-12-01 This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
NCT03345979 ↗ A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia Completed Alkermes, Inc. Phase 3 2017-11-15 This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
NCT04203056 ↗ Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode Recruiting Alkermes, Inc. Phase 4 2019-12-16 This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
NCT04203056 ↗ Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode Recruiting University of California, Los Angeles Phase 4 2019-12-16 This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ARISTADA

Condition Name

Condition Name for ARISTADA
Intervention Trials
Schizophrenia 4
Schizoaffective Disorder, Depressive Type 1
Schizophreniform Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ARISTADA
Intervention Trials
Schizophrenia 4
Psychotic Disorders 1
Disease 1
Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ARISTADA

Trials by Country

Trials by Country for ARISTADA
Location Trials
United States 32
Russian Federation 5
Ukraine 2
Romania 2
Philippines 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ARISTADA
Location Trials
California 4
Texas 3
Missouri 3
Illinois 3
Arkansas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ARISTADA

Clinical Trial Phase

Clinical Trial Phase for ARISTADA
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ARISTADA
Clinical Trial Phase Trials
Completed 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ARISTADA

Sponsor Name

Sponsor Name for ARISTADA
Sponsor Trials
Alkermes, Inc. 4
University of California, Los Angeles 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ARISTADA
Sponsor Trials
Industry 4
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.